Characteristics
Presence (n = 162)
Absence (n = 417)
p Value
Age, y
60.6 ± 13.1
61.6 ± 13.9
nsa
Sex
nsb
Female
110 (67.9 %)
284 (68.1 %)
Male
52 (32.1)
133 (31.9)
Pre-SAH morbidity
nsb
mRS 0-1
156 (96.3)
395 (94.7)
mRS 2-4
6 (3.7)
22 (5.3)
WFNS grade
I
40 (24.7)
129 (30.9)
nsb
II
37 (22.8)
120 (28.8)
nsb
III
18 (11.1)
41 (9.8)
nsb
IV
43 (26.5)
80 (19.2)
nsb
V
24 (14.8)
47 (11.3)
nsb
Fisher CT group
1
0 (0)
7 (1.7)
nsc
2
23 (14.2)
94 (22.5)
<0.05b
3
122 (75.3)
251 (60.2)
<0.001b
4
17 (10.5)
65 (15.6)
nsb
Aneurysm dome, mm
6.6 ± 3.8
6.4 ± 3.4
nsa
neck, mm
3.5 ± 1.7
3.4 ± 1.5
nsa
Aneurysm classification
Small size/small neck
77 (47.5)
212 (50.8)
nsb
Small size/wide neck
57 (35.2)
151 (36.2)
nsb
Large
28 (17.3)
52 (12.5)
nsb
Giant
0 (0)
1 (0.2)
nsc
Aneurysm location
Internal carotid artery
42 (25.9)
133 (31.9)
nsb
Middle cerebral artery
41 (25.3)
90 (21.6)
nsb
Anterior communicating artery
47 (29.0)
115 (27.6)
nsb
Distal anterior cerebral artery
5 (3.1)
23 (5.5)
nsc
Posterior circulation
25 (15.4)
52 (12.5)
nsb
Other
2 (1.2)
4 (1.0)
nsc
Date of aneurysm obliteration
nsb
Days 0–3
152 (93.8)
385 (92.3)
Days 4–12
10 (6.2)
32 (7.7)
Treatment modality
nsb
Clip
89 (54.9)
193 (46.3)
Coil
73 (45.1)
224 (53.7)
Pretreatment re-rupture
15 (9.3)
28 (6.7)
nsb
Intratreatment re-rupture: Clip
26 (16.0)
36 (8.6)
<0.025b
Coil
5 (3.1)
15 (3.6)
nsc
Post-treatment re-rupture
2 (1.2)
10 (2.4)
nsc
Cerebrospinal fluid drainage
119 (73.5)
263 (63.1)
<0.025b
Antiplatelet therapy
38 (23.5)
104 (24.9)
nsb
Symptomatic vasospasm
103 (63.6)
23 (5.5)
<0.001b
Endovascular treatment for vasospasm
48 (29.6)
17 (4.1)
<0.001b
Infection
19 (11.7)
31 (7.4)
nsb
Noninfectious cardiopulmonary complication
8 (4.9)
29 (7.0)
nsc
Epilepsy
7 (4.3)
21 (5.0)
nsc
Shunt-dependent hydrocephalus
43 (26.5)
68 (16.3)
<0.005b
Table 2
of Behavioral Deficits in Rodents Following Brain Injury Across Species, Gender, and Experimental Model
Data Supporting Glyburide in Ischemic Stroke
Ganglia Damage in Experimental Subarachnoid Hemorrhage
Pretreatment Fails to Provide Neuroprotection Following a Surgically Induced Brain Injury Rat Model
IGF-1 Reduced Rat Pup Germinal Matrix Hemorrhage
Injection of Noncellular Cerebrospinal Fluid from Subarachnoid Hemorrhage Patient into Rat Ventricles Leads to Ventricular Enlargement and Periventricular Injury
Modified Rankin Scale (mRS) at 3 and 12 months in patients with or without cerebral infarction after subarachnoid hemorrhage
Related posts:
of Behavioral Deficits in Rodents Following Brain Injury Across Species, Gender, and Experimental Model
Data Supporting Glyburide in Ischemic Stroke
Ganglia Damage in Experimental Subarachnoid Hemorrhage
Pretreatment Fails to Provide Neuroprotection Following a Surgically Induced Brain Injury Rat Model
IGF-1 Reduced Rat Pup Germinal Matrix Hemorrhage
Injection of Noncellular Cerebrospinal Fluid from Subarachnoid Hemorrhage Patient into Rat Ventricles Leads to Ventricular Enlargement and Periventricular Injury
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
